2,4-dichloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile | 950661-87-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 英文名称: 2,4-dichloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
• 英文别名: 2,4-dichloro-7-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-d]pyrimidine-5-carbonitrile
• CAS: 950661-87-7
• 化学式: C₁₃H₁₆Cl₂N₄OSi
• 分子量: 343.288
• InChiKey: DORIEEQYSAYTHN-UHFFFAOYSA-N

物化性质

• 密度：
  1.30±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.92
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  63.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2,4-dichloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 四丁基氟化铵 、 potassium carbonate 、 乙二胺 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 0.42h， 生成 2-chloro-4-(2,4-dimethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
  参考文献：
  名称：

  WO2007/104944

  摘要：

  公开号：
• 作为产物：
  描述：

  2,4-二氯-7H吡咯[2,3-D]嘧啶 在 N-碘代丁二酰亚胺 、 sodium hydride 作用下， 以 N-甲基吡咯烷酮 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 8.0h， 生成 2,4-dichloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
  参考文献：
  名称：

  [EN] COMPOUND, COMPOSITIONS, AND METHODS
  [FR] COMPOSÉS, COMPOSITIONS, ET PROCÉDÉS

  摘要：

  披露了具有LRRK2抑制剂活性的化合物。这些化合物具有公式(I)，包括立体异构体、互变异构体、药物可接受的盐和前药。还披露了与这些化合物的制备和使用相关的方法，以及包含这些化合物的药物组合物。

  公开号：

  WO2017087905A1

文献信息

• [EN] COMPOUND, COMPOSITIONS, AND METHODS<br/>[FR] COMPOSÉS, COMPOSITIONS, ET PROCÉDÉS
  申请人：DENALI THERAPEUTICS INC

  公开号：WO2017087905A1

  公开（公告）日：2017-05-26

  Compounds having activity as LRRK2 inhibitors are disclosed. The compounds are of formula (I) including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

  披露了具有LRRK2抑制剂活性的化合物。这些化合物具有公式(I)，包括立体异构体、互变异构体、药物可接受的盐和前药。还披露了与这些化合物的制备和使用相关的方法，以及包含这些化合物的药物组合物。
• PYRROLOPYRIMIDINE AND PURINE DERIVATIVES
  申请人：Cheng Hengmiao

  公开号：US20130079324A1

  公开（公告）日：2013-03-28

  The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, T, V, W, X, Y, Z, ring A, R 1 , R 2 , R 3 , R 4 , R 5 , R 5a , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 and m are defined herein. There novel pyrrolopyrimidine and purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.

  本发明涉及式（I）的化合物或其药学上可接受的盐，其中Q、T、V、W、X、Y、Z、环A、R1、R2、R3、R4、R5、R5a、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17和m在此定义。这些新颖的吡咯嘧啶和嘌呤衍生物在哺乳动物中治疗异常细胞生长，如癌症方面具有用处。另外，本发明还涉及含有这些化合物的药物组合物，以及在哺乳动物中治疗异常细胞生长的方法。
• PYRROLO-PYRIMIDINE DERIVATIVE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME COMPOUND AS EFFECTIVE INGREDIENT FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE
  申请人：DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION

  公开号：US20200239474A1

  公开（公告）日：2020-07-30

  The present invention relates to a novel pyrrolo-pyrimidine derivative compound, a preparation method therefor, and a pharmaceutical composition comprising the same compound as an effective ingredient for preventing or treating a protein kinase-related disease. The compound represented by Chemical Formula 1 according to the present invention, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an effective ingredient has outstanding inhibitory activity against LRRK2 kinase and against phosphorylation in the NIH-3T3 cell line, which is an LRRK2-expressing cell line, and NCC01 and 448T cell lines, which are both derived from patients with brain tumors. Verified to have inhibitory activity against various protein kinases in addition to LRRK2, the compound can find effective applications in the treatment or prevention of protein kinase-related diseases.

  本发明涉及一种新型吡咯-嘧啶衍生物化合物，其制备方法和制备以该化合物为有效成分的药物组合物，用于预防或治疗蛋白激酶相关疾病。根据本发明，化学式1所表示的化合物、其光学异构体或其药学上可接受的盐，以及包含其作为有效成分的药物组合物，具有对LRRK2激酶和对NIH-3T3细胞系（一种LRRK2表达细胞系）以及NCC01和448T细胞系（均来源于脑肿瘤患者）的磷酸化具有显著的抑制活性。该化合物已经被证实对除LRRK2外的各种蛋白激酶具有抑制活性，因此可以在蛋白激酶相关疾病的治疗或预防中发挥有效作用。
• Pyrrolopyrimidine and purine derivatives
  申请人：Cheng Hengmiao

  公开号：US09040547B2

  公开（公告）日：2015-05-26

  The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, T, V, W, X, Y, Z, ring A, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17 and m are defined herein. There novel pyrrolopyrimidine and purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.

  本发明涉及式(I)的化合物或其药学上可接受的盐，其中Q、T、V、W、X、Y、Z、环A、R1、R2、R3、R4、R5、R5a、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17和m在此定义。这些新型吡咯吡嗪和嘌呤衍生物在哺乳动物的异常细胞生长，如癌症治疗中有用。另外，还涉及含有这些化合物的制药组合物以及在哺乳动物的异常细胞生长治疗中使用这些化合物和组合物的方法。
• Pyrrolopyrimidine Derivatives Used As HSP90 Inhibitors
  申请人：Brough Paul Andrew

  公开号：US20090163490A1

  公开（公告）日：2009-06-25

  Compounds of formula (I) have HSP90 inhibitory activity and are therefore useful in the treatment of, inter alia, cancer: Formula (I) wherein R i is hydrogen, fluoro, chloro, bromo, or a radical of formula -X-Alk 1 -(Z) m -(Alk 2 )n-Q wherein X is —O—, —S— —S(O)—, SO 2 —, or —NH—, Z is —O—, —S—, —(C═O)—, —(C═S)—, —S(O)—, —SO 2 —, —NR A —, or, in either orientation —C(═O)O—, —C(═O)NR A —, —C(═S)NR A —, —SO 2 NR A —, —NR A C(═O)—, or —NR A SO 2 — wherein R A is hydrogen or C 1 -C 6 alkyl AIk 1 and AIk 2 are optionally substituted divalent C 1 -C 3 alkylene or C 2 -C 3 alkenylene radicals, m, n and p are independently 0 or 1, and Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical; R 2 is a radical of formula —(Ar 1 ) p -(Alk 1 ) q -(Z) r -(Alk 2 ) s -Q wherein Ar 1 is an optionally substituted aryl or heteroaryl radical, Alk 1 , Alk 2 , Z, and Q are as defined above, and p, q, r and s are independently 0 or 1; and R 3 is cyano (—CN), fluoro, chloro, bromo, methyl in which in which one or more hydrogen atoms are optionally replaced by fluorine atoms, ethyl in which in which one or more hydrogen atoms are optionally replaced by fluorine atoms, cyclopropyl, —OH, —CH 2 OH, —C(O)NH 2 , —C(O)CH 3 , Or —NH 2 .

  公式（I）的化合物具有HSP90抑制活性，因此在治疗癌症等疾病方面非常有用：公式（I）其中Ri为氢、氟、氯、溴或公式-X-Alk1-(Z)m-(Alk2)n-Q的基团，其中X为-O-，-S-，-S（O）-，SO2-或-NH-，Z为-O-，-S-，-(C═O)-，-(C═S)-，-S(O)-，-SO2-，-NRA-，或以任何方向为-C（═O）O-，-C（═O）NRA-，-C（═S）NRA-，-SO2NRA-，-NRAC（═O）-或-NRASO2-，其中RA为氢或C1-C6烷基，Alk1和Alk2为可选取代的二价C1-C3烷基或C2-C3烯基基团，m、n和p独立地为0或1，Q为氢或可选取代的碳环或杂环基团；R2为公式-(Ar1)p-(Alk1)q-(Z)r-(Alk2)s-Q的基团，其中Ar1为可选取代的芳基或杂芳基基团，Alk1、Alk2、Z和Q如上所定义，p、q、r和s独立地为0或1；R3为氰（-CN）、氟、氯、溴、甲基，其中一个或多个氢原子可选地被氟原子替换，乙基，其中一个或多个氢原子可选地被氟原子替换，环丙基，-OH，-CH2OH，-C（O）NH2，-C（O）CH3或-NH2。